Gem Aromatics IPO: Essential oil-maker raises ₹135 crore from anchor investors ahead of public issue
Gem Aromatics allocated a total of 41,65,383 or more than 41 lakh equity shares with the face value of ₹ 2 apiece to the anchor investors at an allocation price of ₹ 325 per share, the company informed BSE through the filing.
Out of the total anchor allocation for the public issue, none of the equity shares were allocated to any mutual funds through any schemes.
Citigroup Global, Societe Generale, Goldman Sachs, Nippon India, SageOne, Nuvama, and Niveshaay Sambhav Fund were among the top investors who invested in the company's anchor round ahead of the IPO.
Nippon India at 22.16%, SageOne at 11.08%, and Nuvama at 7.39%, were the top allocations of the anchor book round of the Gem Aromatics IPO on Monday, 18 August 2025.
As of Monday, 18 August 2025, the grey market premium (GMP) for the Gem Aromatics IPO stood at ₹ 28 per share. With the upper price band of the public issue at ₹ 325, the shares of the company are expected to be listed at ₹ 353 apiece, marking a premium of 8.62%, according to Investorgain data.
Grey market premium (GMP) is the investors' willingness to pay more for a primary issue in the stock market. The GMP history shows that the GMP dropped to its current levels of ₹ 28 per share on Monday, compared to its ₹ 35 per share level on Sunday, 17 August 2025.
Gem Aromatics is offering a book-built issue of a combination of fresh issue of equity shares up to ₹ 175 crore, and an offer for sale (OFS) component of 85 lakh equity shares by the promoter and investor selling stakeholders.
The IPO is set to open for public bidding on Tuesday, 19 August 2025, and is scheduled to close on Thursday, 21 August 2025. The company has fixed the price band for the IPO in the range of ₹ 309 to ₹ 325 per share, with a lot size of 46 shares per lot.
The company aims to repay or prepay certain loans up to ₹ 140 crore, and the rest of the funds raised from the IPO will be used for general corporate purposes.
Motilal Oswal Investment Advisors Ltd is the book runner for the public issue, while Kfin Technologies Ltd is the registrar of the offer.
Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
an hour ago
- Economic Times
Aurobindo Pharma closing in on $5.5b Zentiva buyout
Boost to Aurobindo's European footprint Live Events Change of hands (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Mumbai: Aurobindo Pharma has emerged as the frontrunner to acquire Prague-based generic drugmaker Zentiva for $5-5.5 billion (Rs 43,500-47,900 crore) from Advent International , said several people aware of the matter, underscoring the growing consolidation of pharmaceutical assets in successful, this will be the largest-ever acquisition by an Indian pharma company, both at home and abroad, trumping the $3.2-billion acquisition of Daiichi Sankyo's stake in Ranbaxy in 2014, or Biocon Biologics' $3.3 billion cash and stock buyout of the global biosimilars business of US-based is competing with US private equity firm GTCR , the other serious contender left in the fray. Both sides are engaged in intense negotiations to finalise the various commercial and operations aspects of the late last year, Advent has been engaged with advisers Goldman Sachs and boutique investment bank PJT Partners to explore exit options for Zentiva, which it acquired seven years were made to several financial investors, including TPG and pharma competitors worldwide for a potential takeover.'The competition heated up from May. The binding offers have been submitted a few weeks ago and ongoing discussions have reached an advanced stage,' said a PE executive involved in the matter. 'Price is no longer being negotiated… A formal announcement can happen in the next fortnight or a month.'Zentiva will significantly boost Aurobindo's European footprint, specifically in the east European region–Czech Republic, Romania and Slovakia—where the market is seen as fertile and steadily warming up to a raft of biosimilars, following patent expiries of big prescription brands. Besides, as most healthcare spending in eastern Europe is led by government bulk public procurement, the returns are steadier as compared to perpetual price erosion in the revenues from Europe are already the highest among all other homegrown pharma peers. For calendar 2024, Zentiva Group's revenues were 1.7 billion euros ($1.98 billion) at an ebitda of 400 million euros ($467 million). Even then, analysts are surprised at the boldness of the bet that the Hyderabad-based company is willing to take amid heightened geopolitical risks and tariff market value stands at Rs 63,684.90 crore ($7.4 billion), whereas Zentiva is privately held. According to people aware of developments, Aurobindo has already secured a $4.75-billion credit line from MUFG–the sole financier in the transaction–as a bridge loan for the transaction. The remaining $800 million will be from the company's internal and Zentiva didn't respond to queries. Advent and MUFG declined to was the first to report on the Zentiva sale last November and on Aurobindo's interest in July this origins that can be traced back to Black Eagle Pharmacy from the 15th century, Zentiva was nationalised in 1946 and has undergone several ownership changes, including one in 1998 when the management team had taken over a majority share to refocus on branded generics. A decade later, in 2009, it got acquired by Sanofi and in 2018, got carved out by Advent for $2.4 billion, a deal process that had even seen a preliminary interest from India's Torrent the years, it has diversified its presence across categories such as prescription drugs, OTC products and consumer health and food supplements as well as geographies, growing both organically and through a series of buyouts across the region. It currently operates in 30 countries and has set a goal to reach one in five people across Europe by India, Zentiva has a manufacturing site in Gujarat. In 2022, Polish firm Pol Pharma, backed by a few private equity players, was reported to have placed a $3.5-billion bid for Zentiva, but the discussions remained inconclusive as the owners were reportedly considering a public leading drugmakers such as Biocon and, more recently, Lupin, have struck separate deals with Zentiva to push their biosimilars in the European region. Aurobindo is developing a robust pipeline of biosimilars such as denosumab (Prolia) for osteoporosis as well as omalizumab (Xolair) and bevacizumab (Avastin) for multiple cancer treatments.'While pricing pressure persists in chronic therapies, the European Union (EU) remains attractive for oncology and retail segments. Ongoing investments in EU-focused capacity continue to support volume growth,' said Amey Chalke of JM EU business of Aurobindo reported 9% revenue growth in the June quarter, from a year ago, with a strong performance across major markets and is on track to cross 1 billion euros in annual revenue in FY26. Injectables grew about 20% from the year earlier, driven by shortage-led demand. Two new oncology lines are being added to meet rising needs, as per the company also received four biosimilar approvals with commercial supplies initiated in the UK and full ramp-up expected in the third or fourth quarter of this fiscal. Aurobindo is targeting 40–60% margins in the EU biosimilar segment and aims for a blended 50% gross margin. Inhouse manufacturing now exceeds half the total formulations volumes, thereby boosting margins, inching toward 20% Aurobindo's FY25 consolidated sales of Rs 31,724 crore ($3.6 billion), the US market accounted for Rs 14,186 crore, up 6.8% from the year earlier. The European business grew 16.6% to Rs 8,356 month, Aurobindo acquired US-based contract development and manufacturing organization (CDMO) player Lannett for $250 million to shore up its manufacturing presence in the US while enhancing its capabilities in manufacturing complex generic drugs such as controlled at least three previous occasions, Aurobindo has either lost out to rivals or had to back out of marque transactions after announcing them. In 2020, it had to call off its deal to acquire the oral solids and dermatology business of Sandoz (part of Novartis) in the US for $900 million, failing to receive due approvals from US Federal Trade Commission even after two years.
Time of India
an hour ago
- Time of India
Aurobindo Pharma closing in on $5.5b Zentiva buyout
Tired of too many ads? Remove Ads Boost to Aurobindo's European footprint Tired of too many ads? Remove Ads Change of hands Tired of too many ads? Remove Ads Mumbai: Aurobindo Pharma has emerged as the frontrunner to acquire Prague-based generic drugmaker Zentiva for $5-5.5 billion (Rs 43,500-47,900 crore) from Advent International , said several people aware of the matter, underscoring the growing consolidation of pharmaceutical assets in successful, this will be the largest-ever acquisition by an Indian pharma company, both at home and abroad, trumping the $3.2-billion acquisition of Daiichi Sankyo's stake in Ranbaxy in 2014, or Biocon Biologics' $3.3 billion cash and stock buyout of the global biosimilars business of US-based is competing with US private equity firm GTCR , the other serious contender left in the fray. Both sides are engaged in intense negotiations to finalise the various commercial and operations aspects of the late last year, Advent has been engaged with advisers Goldman Sachs and boutique investment bank PJT Partners to explore exit options for Zentiva, which it acquired seven years were made to several financial investors, including TPG and pharma competitors worldwide for a potential takeover.'The competition heated up from May. The binding offers have been submitted a few weeks ago and ongoing discussions have reached an advanced stage,' said a PE executive involved in the matter. 'Price is no longer being negotiated… A formal announcement can happen in the next fortnight or a month.'Zentiva will significantly boost Aurobindo's European footprint, specifically in the east European region–Czech Republic, Romania and Slovakia—where the market is seen as fertile and steadily warming up to a raft of biosimilars, following patent expiries of big prescription brands. Besides, as most healthcare spending in eastern Europe is led by government bulk public procurement, the returns are steadier as compared to perpetual price erosion in the revenues from Europe are already the highest among all other homegrown pharma peers. For calendar 2024, Zentiva Group's revenues were 1.7 billion euros ($1.98 billion) at an ebitda of 400 million euros ($467 million). Even then, analysts are surprised at the boldness of the bet that the Hyderabad-based company is willing to take amid heightened geopolitical risks and tariff market value stands at Rs 63,684.90 crore ($7.4 billion), whereas Zentiva is privately held. According to people aware of developments, Aurobindo has already secured a $4.75-billion credit line from MUFG–the sole financier in the transaction–as a bridge loan for the transaction. The remaining $800 million will be from the company's internal and Zentiva didn't respond to queries. Advent and MUFG declined to was the first to report on the Zentiva sale last November and on Aurobindo's interest in July this origins that can be traced back to Black Eagle Pharmacy from the 15th century, Zentiva was nationalised in 1946 and has undergone several ownership changes, including one in 1998 when the management team had taken over a majority share to refocus on branded generics. A decade later, in 2009, it got acquired by Sanofi and in 2018, got carved out by Advent for $2.4 billion, a deal process that had even seen a preliminary interest from India's Torrent the years, it has diversified its presence across categories such as prescription drugs, OTC products and consumer health and food supplements as well as geographies, growing both organically and through a series of buyouts across the region. It currently operates in 30 countries and has set a goal to reach one in five people across Europe by India, Zentiva has a manufacturing site in Gujarat. In 2022, Polish firm Pol Pharma, backed by a few private equity players, was reported to have placed a $3.5-billion bid for Zentiva, but the discussions remained inconclusive as the owners were reportedly considering a public leading drugmakers such as Biocon and, more recently, Lupin, have struck separate deals with Zentiva to push their biosimilars in the European region. Aurobindo is developing a robust pipeline of biosimilars such as denosumab (Prolia) for osteoporosis as well as omalizumab (Xolair) and bevacizumab (Avastin) for multiple cancer treatments.'While pricing pressure persists in chronic therapies, the European Union (EU) remains attractive for oncology and retail segments. Ongoing investments in EU-focused capacity continue to support volume growth,' said Amey Chalke of JM EU business of Aurobindo reported 9% revenue growth in the June quarter, from a year ago, with a strong performance across major markets and is on track to cross 1 billion euros in annual revenue in FY26. Injectables grew about 20% from the year earlier, driven by shortage-led demand. Two new oncology lines are being added to meet rising needs, as per the company also received four biosimilar approvals with commercial supplies initiated in the UK and full ramp-up expected in the third or fourth quarter of this fiscal. Aurobindo is targeting 40–60% margins in the EU biosimilar segment and aims for a blended 50% gross margin. Inhouse manufacturing now exceeds half the total formulations volumes, thereby boosting margins, inching toward 20% Aurobindo's FY25 consolidated sales of Rs 31,724 crore ($3.6 billion), the US market accounted for Rs 14,186 crore, up 6.8% from the year earlier. The European business grew 16.6% to Rs 8,356 month, Aurobindo acquired US-based contract development and manufacturing organization (CDMO) player Lannett for $250 million to shore up its manufacturing presence in the US while enhancing its capabilities in manufacturing complex generic drugs such as controlled at least three previous occasions, Aurobindo has either lost out to rivals or had to back out of marque transactions after announcing them. In 2020, it had to call off its deal to acquire the oral solids and dermatology business of Sandoz (part of Novartis) in the US for $900 million, failing to receive due approvals from US Federal Trade Commission even after two years.
Hindustan Times
an hour ago
- Hindustan Times
TikTok ban update: Trump and White House make big move; positive news for fans
While President Donald Trump has about a month to finalize the sale of TikTok or send the video-sharing platform into a ban, the White House has made a massive move. The Trump administration on Tuesday started a TikTok account, and fans now think that the China-based application is here to stay. A 3D-printed miniature model of Donald Trump and TikTok logo are seen in this illustration(REUTERS) This comes as Trump has time and again discussed the sale of TikTok, citing its Chinese ownership. ByteDance had first faced a deadline for the sale of the platform earlier this year. However, the deadline was pushed. On Tuesday, the White House launched an official TikTok account. 'The Trump administration is committed to communicating the historic successes President Trump has delivered to the American people with as many audiences and platforms as possible," White House press secretary Karoline Leavitt said as the site went live. "President Trump's message dominated TikTok during his presidential campaign, and we're excited to build upon those successes and communicate in a way no other administration has before,' she added. White House's first video on TikTok In the first video posted on the new account, dramatic music plays over a compilation of President Trump meeting people. "Every day I wake up determined to deliver a better life for the people all across this nation," Trump says in the 27-second video. 'I am your voice,' he adds. The clip received over 7,500 likes and more than 500 comments in less than an hour. TikTok users excited While the White House did not mention whether the new account is an indication of the sale of TikTok, several users were excited. 'White House rolled out a TikTok account. Something tells me the ban isn't coming anytime soon,' one person noted on X, platform formerly known as Twitter. 'Back in my day, White House was going to ban TikTok. We live in interesting times! 🤔' another person tweeted.
